Short Bowel Syndrome Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma

DelveInsight's "Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Short Bowel Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Short Bowel Syndrome Market Forecast
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Short Bowel Syndrome Market Report:
• The Short Bowel Syndrome market size was valued approximately USD 2.3 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, the United States reported the highest number of cases among the seven major markets, with a prevalence of 20,800 cases.
• In 2022, Germany had the highest prevalence of Short Bowel Syndrome cases among the European Union Four (EU4) and the United Kingdom, with approximately 2,700 reported cases.
• According to information released by the Crohn's & Colitis Foundation of America, an estimated 10,000 to 20,000 individuals in the United States are affected by Short Bowel Syndrome.
• According to information provided by PINNT, approximately 1,000 individuals in England are believed to have Short Bowel Syndrome, necessitating ongoing treatment with parenteral nutrition support.
• Emerging therapies for Short Bowel Syndrome (SBS) comprise Glepaglutide, Apraglutide, HM15912, and various others. Ongoing research suggests the potential development of enhanced pharmacologic treatments targeting improved intestinal adaptation, regulation of gut motility, management of small bowel bacterial overgrowth, and addressing rejection issues following small intestinal transplantation.
• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• The Short Bowel Syndrome epidemiology based on gender analyzed that Short Bowel Syndrome affects females more than males
• The Short Bowel Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Short Bowel Syndrome pipeline products will significantly revolutionize the Short Bowel Syndrome market dynamics.

Short Bowel Syndrome Overview
Short Bowel Syndrome (SBS) is a rare and complex digestive disorder that occurs when a significant portion of the small intestine is either missing or nonfunctional. The small intestine is responsible for absorbing nutrients and fluids from the food we eat. When a large part of it is removed or nonfunctional due to surgical resection, injury, or a congenital condition, it can lead to malabsorption of nutrients, electrolyte imbalances, and dehydration.

Get a Free sample for the Short Bowel Syndrome Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Short Bowel Syndrome Epidemiology Segmentation:
The Short Bowel Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Short Bowel Syndrome
• Prevalent Cases of Short Bowel Syndrome by severity
• Gender-specific Prevalence of Short Bowel Syndrome
• Diagnosed Cases of Episodic and Chronic Short Bowel Syndrome

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ Short Bowel Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Short Bowel Syndrome market or expected to get launched during the study period. The analysis covers Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Short Bowel Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Short Bowel Syndrome Therapies and Key Companies
• Glepaglutide: Zealand Pharma
• Apraglutide: Ironwood Pharmaceuticals
• HM15912: Hanmi Pharmaceutical
• Teduglutide: Shire
• Pancreatic Enzyme: AbbVie
• HM15912 Active: Hanmi Pharma
• Somatropin: EMD Serono
• ZP1848: Zealand Pharma
• FE203799: VectivBio AG
• Clinolipid: Baxter Healthcare

Discover more about therapies set to grab major Short Bowel Syndrome market share @ Short Bowel Syndrome Treatment Landscape
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Short Bowel Syndrome Market Strengths
• In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
• Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

Short Bowel Syndrome Market Opportunities
• Several organizations are actively working to provide information and increase awareness of such disorders.
• There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome

Scope of the Short Bowel Syndrome Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
• Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
• Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Short Bowel Syndrome Unmet Needs, KOL's views, Analyst's views, Short Bowel Syndrome Market Access and Reimbursement

To know more about Short Bowel Syndrome companies working in the treatment market, visit @ Short Bowel Syndrome Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Short Bowel Syndrome Market Report Introduction
2. Executive Summary for Short Bowel Syndrome
3. SWOT analysis of Short Bowel Syndrome
4. Short Bowel Syndrome Patient Share (%) Overview at a Glance
5. Short Bowel Syndrome Market Overview at a Glance
6. Short Bowel Syndrome Disease Background and Overview
7. Short Bowel Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Short Bowel Syndrome
9. Short Bowel Syndrome Current Treatment and Medical Practices
10. Short Bowel Syndrome Unmet Needs
11. Short Bowel Syndrome Emerging Therapies
12. Short Bowel Syndrome Market Outlook
13. Country-Wise Short Bowel Syndrome Market Analysis (2019-2032)
14. Short Bowel Syndrome Market Access and Reimbursement of Therapies
15. Short Bowel Syndrome Market Drivers
16. Short Bowel Syndrome Market Barriers
17. Short Bowel Syndrome Appendix
18. Short Bowel Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Short Bowel Syndrome Pipeline https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Short Bowel Syndrome Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Short Bowel Syndrome market. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided, which includes the disease overview and Short Bowel Syndrome treatment guidelines.
Short Bowel Syndrome Epidemiology https://www.delveinsight.com/report-store/short-bowel-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Short Bowel Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Short Bowel Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.